(Q35543618)

8 August 2017

1 reference

title

Organ allocation: model for end-stage liver disease, Child-Turcotte-Pugh, Mayo risk score, or something else (English)

1 reference

8 August 2017

main subject

end-stage liver disease

1 reference

inferred from title

author name string

Rafael Claudino Botero

1

1 reference

8 August 2017

Michael R. Lucey

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14509535

14 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14509535

14 March 2024

publication date

1 August 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S1089326103000527?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00052-7

https://api.elsevier.com/content/article/PII:S1089326103000527?httpAccept=text/plain

14 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00052-7

14 March 2024

published in

Clinics in liver disease

1 reference

8 August 2017

volume

7

1 reference

8 August 2017

issue

3

1 reference

8 August 2017

page(s)

715-27, ix

1 reference

Liver transplantation with use of cyclosporin a and prednisone

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

A Comparison of Tacrolimus (FK 506) and Cyclosporine for Immunosuppression in Liver Transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

RS-61443--a new, potent immunosuppressive agent

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Compensated cirrhosis: Natural history and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Survival and prognostic indicators in compensated and decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Transection of the oesophagus for bleeding oesophageal varices

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Prognostic factors in cirrhosis identified by Cox's regression model.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Prognosis and life expectancy in chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo End-stage Liver Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

A peek at the child-turcotte classification

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

MELD and PELD: application of survival models to liver allocation

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Primary biliary cirrhosis: survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Primary biliary cirrhosis: clinical features and outcome, with special reference to asymptomatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Serum bilirubin: a prognostic factor in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Prognosis in primary biliary cirrhosis: model for decision making

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Is primary sclerosing cholangitis a progressive disease or not?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Current concepts in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Primary sclerosing cholangitis: findings on cholangiography and pancreatography

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Cholangiocarcinoma Complicating Primary Sclerosing Cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900052-7

7 January 2021

Surgery and portal hypertension

11

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00052-7

Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?

14 March 2024

42

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00052-7

Primary sclerosing cholangitis: the emerging role for liver transplantation

14 March 2024

49

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00052-7

14 March 2024

Identifiers

1 reference

8 August 2017

1 reference